@FiercePharma: GSK's vaccine unit sees revenue, profit jump in Q3. More from FierceVaccines | Follow @FiercePharma
@CarlyHFierce: Good thing Bayer's in Germany, CEO says. U.S. business culture is too impatient. Story | Follow @CarlyHFierce
> The FTC has approved Mylan's ($MYL) hostile bid for Perrigo ($PRGO) under the condition that Mylan sell 7 drugs to Alvogen. Report
> Another surge in Eylea sales drove Regeneron ($REGN) to a 57% increase in Q3 revenue, and net income more than doubled. Report
> Johnson & Johnson's ($JNJ) Janssen unit submitted an application for expanded European approval of its blood cancer drug Imbruvica, as a therapy for previously untreated patients with chronic lymphocytic leukemia. Release
Medical Device News
@FierceMedDev: Roche launches rapid HIV, hep C tests in Europe. Article | Follow @FierceMedDev
@VarunSaxena2: Medtronic releases health economics study of its drug-coated balloon at Las Vegas conference. Story | Follow @VarunSaxena2
@EmilyWFierce: Does AstraZeneca own the color purple? On a pill, yes, the company contends. FiercePharmaMarketing story | Follow @EmilyWFierce
> Theranos CEO heeds call for transparency for proprietary technology. Article
> Medtronic axes 150 jobs in new Irish tax domicile. News
Biotech News
@FierceBiotech: Biogen spells out its moonshot R&D strategy amid deep cost cuts. More | Follow @FierceBiotech
@JohnCFierce: Oxford team spotlights promise of AstraZeneca drug in targeting cancers. FierceBiotechResearch article | Follow @JohnCFierce
> Flagship launches another microbiome biotech with $35M and a focus on cancer. Report
> Allergan bets $50M on a dry eye drug as it touts its commitment to R&D. Story
> Vertex looks to gene therapy, RNA deals to quash takeover talk. Article
Pharma Marketing News
> GlaxoSmithKline's HIV bright spot could get brighter with new Tivicay combo meds. Item
> Viewers skeptical of DTC ads, but they drive people to docs anyway. More
> Bristol-Myers Q3 ad spending pushes up to $193M on renewed promotions push. Story
> Pfizer launches first Prevnar TV spot to bring in the 50-plus crowd. Report
> Does AstraZeneca own the color purple? On a pill, yes, the company contends. Article
Biotech Research News
> Neat 'trick' guards peptides against early degradation. Story
> JAK inhibitors target senescent cells in aging study. Item
> Small molecule used to blunt glioblastoma growth in mice--UCSD. More
> Researchers devise heat-triggered liposome 'grenades' to destroy cancer cells. Story
> UPenn researchers show importance of calcium signaling for Ebola virus. Article
Vaccines News
> Takeda, Hilleman eye low-cost vaccine space. News
> Sanofi expects first dengue vaccine license in Q4. Item
> Pfizer teams up with the Biovac Institute to produce Prevenar 13 in South Africa. Report
> GSK's vaccine unit sees revenue, profit jump in Q3. Story
> European Commission launches €23M HIV vaccine research initiative. Article
And Finally... These days, it's common to see several drugs racing for a first-in-class approval, which means that small accelerations in R&D can yield big payoffs, a Tufts University study found. Report